Johns Hopkins Researchers Present Advances In Prostate Cancer Program At The Annual Meeting Of The American Urological Association
\"We are pleased with the progress of our ongoing collaborative prostate cancer program with Johns Hopkins. These findings address a critical aspect of the management of prostate cancer, as the ability to predict recurrence can help physicians and patients understand better the aggressiveness of disease,\" said Gail S. Page, President and CEO of Ciphergen. \"The discovery of PCI using Ciphergen\'s technology demonstrates its ability to identify markers directly related to the disease process, since PCI is present in seminal fluid and directly interacts with PSA. Further validation is underway.\"
Ciphergen is dedicated to translating protein biomarkers and panels of biomarkers into protein molecular diagnostic tests that improve patient care. We are also focused on providing collaborative R&D services through our Biomarker Discovery Center(R) laboratories for biomarker discovery for new diagnostic tests as well as pharmacoproteomic services for improved drug toxicology, efficacy and theranostic assays. Ciphergen develops, manufactures and markets a family of ProteinChip(R) Systems and services for clinical, research and process proteomics applications. ProteinChip Systems enable protein discovery, validation, identification and assay development to provide researchers with predictive, multi-marker assay capabilities and a better understanding of biological function at the protein level. Additional information about Ciphergen can be found at http://www.ciphergen.com.
Safe Harbor Statement
Note Regarding Forward-Looking Statements: This press release contains forward-looking statements. For purposes of the Private Securities Litigation Reform Act of 1995 (the \"Act\"), Ciphergen disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such forward-looking statements include statements regarding the usefulness of certain biomarkers to predict the recurrence of disease and the ability of Ciphergen to use such biomarkers in the creation of diagnostic tests. Actual results may differ materially from those projected in such forward-looking statements due to various factors, including the risk that Ciphergen may not be able to develop diagnostic tests based on the discoveries of certain biomarkers. Investors should consult Ciphergen\'s filings with the Securities and Exchange Commission, including its Form 10-K filed March 17, 2006, for further information regarding these and other risks related to the Company\'s business. Ciphergen, ProteinChip and Biomarker Discovery Center are registered trademarks of Ciphergen Biosystems, Inc.
Ciphergen Biosystems, Inc.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Brook, James. "Johns Hopkins Researchers Present Advances In Prostate Cancer Program At The Annual Meeting Of The American Urological Association." Medical News Today. MediLexicon, Intl., 28 May. 2006. Web.
22 Jun. 2017. <http://www.medicalnewstoday.com/releases/44139.php>
Brook, J. (2006, May 28). "Johns Hopkins Researchers Present Advances In Prostate Cancer Program At The Annual Meeting Of The American Urological Association." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.